Your browser doesn't support javascript.
loading
Prevalence of Post-Heart Transplant Malignancies: A Systematic Review and Meta-Analysis.
Lateef, Noman; Farooq, Muhammad Zain; Latif, Azka; Ahmad, Soban; Ahsan, Muhammad Junaid; Tran, Amy; Nickol, Jennifer; Wasim, Muhammad Fahad; Yasmin, Farah; Kumar, Pankaj; Arif, Abdul Wahab; Shaikh, Asim; Mirza, Mohsin.
Afiliação
  • Lateef N; Department of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NB. Electronic address: noman.mlateef@gmail.com.
  • Farooq MZ; Department of Hematology/Oncology, Moffitt Cancer Center, Florida, FL.
  • Latif A; Department of Cardiovascular Medicine, Baylor University, Houston, TX.
  • Ahmad S; Department of Internal Medicine, East Carolina University, NC.
  • Ahsan MJ; Division of Cardiovascular Medicine, Iowa Heart Center, Iowa.
  • Tran A; Department of Internal Medicine, Creighton University, NB.
  • Nickol J; Department of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NB.
  • Wasim MF; Department of Medicine, Baqai Medical University, Karachi, Pakistan.
  • Yasmin F; Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
  • Kumar P; Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
  • Arif AW; Department of Cardiovascular Medicine, Cook County Health Sciences, Chicago, IL.
  • Shaikh A; Department of Internal Medicine, Rochester General Hospital, Rochester, NY.
  • Mirza M; Department of Internal Medicine, Creighton University, NB.
Curr Probl Cardiol ; 47(12): 101363, 2022 Dec.
Article em En | MEDLINE | ID: mdl-36007618
ABSTRACT
The prevalence of different cancers after heart transplant (HT) is unclear due to small and conflicting prior studies. Herein, we report a systematic review and meta-analysis to highlight the prevalence and pattern of malignancies post-HT. We conducted an extensive literature search on PubMed, Scopus, Cochrane databases for prospective or retrospective studies reporting malignancies after HT. The proportions from each study were subjected to random effects model that yielded the pooled estimate with 95% confidence intervals (CI). Fifty-five studies comprising 60,684 HT recipients reported 7759 total cancers during a mean follow-up of 9.8 ± 5.9 years, with an overall incidence of 15.3% (95% CI = 12.7%-18.1%). Mean time from HT to cancer diagnosis was 5.1 ± 4 years. The most frequent cancers were gastrointestinal (7.6%), skin (5.7%), and hematologic/blood (2.5%). Meta-regression showed no association between incidence of cancer and mean age at HT (coeff -0.008; P = 0.25), percentage of male recipients (coeff -0.001; P = 0.81), donor age (coeff -0.011; P = 0.44), 5-year (coeff 0.003; P = 0.12) and 10-year (coeff 0.02; P = 0.68) post-transplant survival. There is a substantial risk of malignancies in HT recipients, most marked for gastrointestinal, skin, and hematologic. Despite their occurrence, survival is not significantly impacted.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Coração / Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Coração / Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article